Glimepiride
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- South Korea
- Payment Terms
- Negotiable
- Production method
- Negotiable
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- active pharmaceutical ingredient, api, glimepiride
- Category
- Pharmaceuticals , Other Pharmaceutical Chemicals
Inist ST
- Membership
- VIP
- Recent Visit
- Dec 31, 2024
- Country / Year Established
-
South Korea
/
2000
- Business type
- Manufacturer
- Verified Certificate
-
17
| Product name | Glimepiride | Certification | - |
|---|---|---|---|
| Category |
Pharmaceuticals
Other Pharmaceutical Chemicals |
Ingredients | - |
| Keyword | active pharmaceutical ingredient , api , glimepiride | Unit Size | - |
| Brand name | - | Unit Weigh | - |
| origin | South Korea | Stock | - |
| Supply type | - | HS code | - |
Product Information
Glimepiride
| Category |
Antidiabetic
| Spec |
JP / EP
| Description |
Glimepiride is a medium-to-long acting sulfonylurea anti-diabetic drug.
Glimepiride is an oral diabetes medicine that helps control blood sugar levels.
This medication helps body respond better to insulin produced by pancreas.
Terbinafine is an antifungal antibiotic.It is mainly effective on the dermatophytes group of fungi. It is used to treat infections caused by fungus that affect the fingernails or toenails.
B2B Trade
| Price (FOB) | Negotiable | transportation | - |
|---|---|---|---|
| MOQ | Negotiable | Leadtime | Negotiable |
| Payment Options | Negotiable | Shipping time | Negotiable |
- President
- Kim Kuk-hyun
- Address
- Geumwang-Eup, 500 Shinaero , Eumseong-gun, Chungcheongbuk-do, Korea
- Product Category
- Pharmaceuticals
- Year Established
- 2000
- Company introduction
-
Having persistent enthusiasm, INIST ST is trying to contribute to the society and community by delivering healthier life from age 0 to 110 years through research and innovation. Since its establishment in 2000, INIST ST has been accomplishing rapid growth with passion, confidence and trust between customers and the company. INIST ST has developed non-cytotoxic anti-cancer, high quality generic & value-added API and supplied to the domestic and overseas markets. INIST ST has intensive R&D function in exploration of drug candidate and process development of small molecules. As result of those efforts, INIST ST has achieved multiple crystal and process patents and become partner of several government sponsoring development projects.
- Main Markets
-
Japan
Taiwan
Turkey
U.S.A
- Main Product
